sb 202190 has been researched along with Fasting Hypoglycemia in 1 studies
4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole: structure given in first source; inhibits p38 MAP kinase
Fasting Hypoglycemia: HYPOGLYCEMIA expressed in the postabsorptive state, after prolonged FASTING, or an overnight fast.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Shigiyama, F | 1 |
| Hamanoue, M | 1 |
| Kobayashi, M | 1 |
| Takamatsu, K | 1 |
1 other study available for sb 202190 and Fasting Hypoglycemia
| Article | Year |
|---|---|
Cell-permeable p38 MAP kinase protects adult hippocampal neurons from cell death.
Topics: Animals; Cell Death; Cells, Cultured; Hippocampus; Hypoglycemia; Imidazoles; Mice; Neurons; Neuropro | 2019 |